Sign up for free.
Grunenthal is a global, research-based pharmaceutical company focused on the management of pain and related diseases. The company is committed to the vision of a world free from pain and works with passion to develop innovative, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.
Grunenthal's product portfolio includes both innovative growth products and established medicines, including Qutenza™, Vimovo®, Movantik™/Moventig™, Nexium™, Crestor™, Nebido™ and Tramal™. The company is pursuing four key indications in the field of pain: peripheral neuropathic pain, chronic postoperative pain, chronic back pain and osteoarthritis.
Grunenthal continuously invests in research and development to create new therapy options. Key research programs include a Glucocorticoid Receptor Modulator (GRM) with the potential for improved safety compared to conventional glucocorticoids, a Nociceptin/Orphanin FQ Receptor Peptide Agonist (NOP) for chronic pain, and the development of next-generation voltage-gated sodium channel (NaV) inhibitors.
As a responsible company, Grunenthal attaches great importance to sustainability and pursues a comprehensive ESG approach (Environment, Social and Governance). The company focuses on the areas of Patient, People and Planet to make a positive contribution to society. This includes initiatives for patient safety, product quality, improving the quality of life of patients, responsible handling of opioids, promoting diversity and inclusion, and reducing the ecological footprint.
Grunenthal is committed to its historical responsibility in connection with Thalidomide and supports those affected through the GrĂĽnenthal Stiftung, which finances projects to improve their quality of life. The company is committed to an open dialogue with the Thalidomide community and works together on initiatives that bring long-term benefits.
With around 4,300 employees worldwide and production facilities in Europe and Latin America, Grunenthal is committed to providing patients in over 100 countries with safe and reliable medicines. The company is a member of various industry associations such as EFPIA, IFPMA and PSCI and is committed to the highest ethical and regulatory standards.
